TY PHAR.(SZ:002728) Xin Lang Cai Jing·2025-11-23 00:17Core Viewpoint - The company reported that its core product, Zhi Ke Bao tablets, achieved sales of 104 million tablets in Q3 2025, generating revenue of 69.62 million yuan, indicating a recovery in sales and revenue compared to the same period in 2023 [1] Sales Performance - The sales volume of Zhi Ke Bao tablets in Q3 2025 has recovered to 65.06% of the sales volume in the same period of 2023 [1] - The revenue from Zhi Ke Bao tablets in Q3 2025 has recovered to 96.69% of the revenue in the same period of 2023 [1] Future Plans - The company aims to continue enhancing its self-operated system and plans to achieve an annual sales target of 100 million boxes of Zhi Ke Bao tablets within approximately 3-5 years after the completion of its marketing system reform [1]